<DOC>
	<DOCNO>NCT00929396</DOCNO>
	<brief_summary>The purpose study evaluate safety profile adjuvanted TB subunit vaccine administer 0 2 month .</brief_summary>
	<brief_title>A Safety Immunogenicity Trial With Adjuvanted Tuberculosis ( TB ) Subunit Vaccine Purified Protein Derivative ( PPD ) Positive Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female 18 55 year old BCG group : Known BCGvaccinated 2 year , PPD positive ( range 615 mm document value 615 mm medical file past ) , active , chronic past TB disease confirm chest X ray , negative QuantiFERONTB Gold In Tube test negative 6day lymphocyte test . Infection group : Known treated latent TB , PPDpositive ( equal 10 mm document equal 10 mm positive medical file past ) , previously TB infect active disease confirm chest X ray , may receive chemoprophylaxis TB treatment/chemoprophylaxis within precede 2 year , positive QuantiFERONTB Gold In Tube test and/or positive 6day lymphocyte test . Healthy base medical examination/history inclusion Signed informed consent Prepared grant authorize person access medical record The volunteer likely comply instruction Granulomatous disease ( chest Xray ) Vaccinated live vaccine 3 month first vaccination Administration immune modulate drug ( steroid , immunosuppressive drug immunoglobulin ) 3 month first vaccination HBV , HCV HIV seropositive Participation clinical trial Known hypersensitivity vaccine component Laboratory parameter outside normal range judge PI clinically relevant Pregnant women/planned pregnancy and/or breastfeed within trial period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Ag85B</keyword>
	<keyword>ESAT-6</keyword>
	<keyword>IC31</keyword>
</DOC>